Forsta AP Fonden Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Forsta AP Fonden has reduced its stake in Regeneron Pharmaceuticals by 5.9%, now holding 20,800 shares worth approximately $13.2 million following the sale of 1,300 shares.
• Regeneron reported earnings per share (EPS) of $12.89 for the last quarter, significantly exceeding analyst estimates of $8.43, with a revenue of $3.68 billion.
• The company recently announced a quarterly dividend of $0.88 per share, reflecting a dividend yield of 0.6% and a payout ratio of 8.87%.

Forsta AP Fonden decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,800 shares of the biopharmaceutical company's stock after selling 1,300 shares during the period. Forsta AP Fonden's holdings in Regeneron Pharmaceuticals were worth $13,192,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Pinney & Scofield Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. increased its stake in shares of Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares during the period. Costello Asset Management INC purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at $27,000. Tompkins Financial Corp purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at $32,000. Finally, Curat Global LLC purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at $32,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently commented on REGN. Citigroup restated a "buy" rating and set a $650.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. BMO Capital Markets raised their price target on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a research note on Monday, August 4th. Wells Fargo & Company lowered Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price target on the stock. in a research note on Friday, August 1st. UBS Group reiterated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Finally, Guggenheim lifted their target price on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research note on Friday, August 1st. One analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $841.30.

Regeneron Pharmaceuticals Stock Performance

REGN stock traded up $3.20 during trading on Friday, hitting $563.00. 1,024,297 shares of the company traded hands, compared to its average volume of 978,475. The stock's 50-day simple moving average is $536.80 and its 200 day simple moving average is $598.52. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The company has a market cap of $59.67 billion, a PE ratio of 14.19, a P/E/G ratio of 1.91 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. The company had revenue of $3,675,600 billion during the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. Regeneron Pharmaceuticals's quarterly revenue was up 3.6% on a year-over-year basis. During the same period last year, the business earned $11.56 earnings per share. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be given a $0.88 dividend. The ex-dividend date is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.